Myeloid Malignancy Clinical Trials

9 recruiting

Frequently Asked Questions

Common questions about Myeloid Malignancy clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 19 of 9 trials

Recruiting
Phase 1

Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies

Acute Myeloid LeukemiaHematologic MalignancyMyelodysplastic Syndromes+1 more
University of Alabama at Birmingham20 enrolled1 locationNCT07044544
Recruiting
Not Applicable

A Telehealth Advance Care Planning Intervention

Acute Myeloid LeukemiaMyelodysplastic SyndromesMyelofibrosis+2 more
University of Rochester207 enrolled1 locationNCT05875805
Recruiting
Phase 1Phase 2

Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML

Myeloid MalignancyRelapsed/Refractory Acute Myeloid Leukaemia
Ascentage Pharma Group Inc.458 enrolled12 locationsNCT04501120
Recruiting
Phase 2

Mitoxantrone Hydrochloride Liposome, Standard-dose of Cytarabine and Venetoclax in the Treatment of R/R AML

Myeloid MalignancyRelapsed/Refractory Acute Myeloid Leukaemia
First Affiliated Hospital of Zhejiang University72 enrolled1 locationNCT06621212
Recruiting
Phase 1Phase 2

Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant

Acute Myeloid LeukemiaMyeloid Malignancy
Benjamin Tomlinson20 enrolled1 locationNCT06129734
Recruiting
Phase 1

A Study of GLB-001 in Patients With Myeloid Malignancies

Acute Myeloid LeukemiaMyelodysplastic SyndromesMyelofibrosis+3 more
Hangzhou GluBio Pharmaceutical Co., Ltd.108 enrolled14 locationsNCT06378437
Recruiting
Phase 1

HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML

Acute Myeloid LeukemiaMyelodysplastic SyndromesMyeloid Malignancy
Masonic Cancer Center, University of Minnesota45 enrolled1 locationNCT06594445
Recruiting
Phase 1Phase 2

A Clinical Trial of TQB3909 Tablets in Combination With Azacitidine for the Treatment of Myeloid Malignancies

Myeloid Malignancy
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.138 enrolled21 locationsNCT07011186
Recruiting
Phase 2

Mitoxantrone Hydrochloride Liposome Injection, Cytarabine Combined With Venetoclax in the Treatment of R/R AML

Myeloid MalignancyRelapsed/Refractory Acute Myeloid Leukaemia
First Affiliated Hospital of Zhejiang University34 enrolled1 locationNCT06434662